Annual Information Update

RNS Number : 5056B
Oxford Biomedica PLC
17 April 2012

Oxford BioMedica plc ("Oxford BioMedica" or the "Company")


Annual Information Update for the Twelve Months to 1 April 2012


Oxford BioMedica is providing an annual information update pursuant to Prospectus Rule 5.2 made by the Financial Services Authority.


1.                     Announcements made via a Regulatory Information Service




04 April 2011

Annual Information Update

15 April 2011

Directors' Interest in Shares and Share Options

03 May 2011

Announcement of data in ProSavin® study

04 May 2011

Pfizer license extension

05 May 2011

Annual General Meeting and Board changes

18 May 2011

Interim management statement

23 May 2011

New clinical data from ProSavin® Phase I/II study

24 May 2011

Management and Board changes

26 May 2011

Block listing six monthly return

07 June 2011

Research agreement with ImaginAb

28 June 2011

Notice of results

08 July 2011

Holding(s) in Company

 04 August 2011

Interim data from ProSavin® Phase I/II study

31 August 2011

TR-1: Notification of Major Interest in Shares

 31 August 2011

Interim Results

04 October 2011

TR1 Form

 04 October 2011

TR1 Form

18 October 2011

US IND approval for novel ocular product in Usher syndrome type 1B

16 November 2011

Interim management statement

28 November 2011

Block listing six monthly return

15 December 2011

Interim update on ProSavin® Phase I/II study

16 December 2011

Directors' interest in shares

30 January 2012

Notification of Major Interest in Shares

10 February 2012

Management and Board change

24 February 2012

Notice of results

06 March 2012

Preliminary results

08 March 2012

Director / PDMR dealings

12 March 2012

Significant shareholding

22 March 2012

TR-1 Notification of Major Interest in Shares


Details of all regulatory announcements for Oxford BioMedica can be found on the London Stock Exchange website at  and on the Oxford BioMedica website at 



2.                  Documents filed with Companies House



Document type


9 May 2011


Resolution to authorise and allot shares and debentures, to extend share option scheme and to disapply pre-emption rights

11 May 2011


Annual Accounts

29 July 2011


Termination of appointment, director - Alan Kingsman

29 July 2011


Termination of appointment, director - Alexander Lewis

27 September 2011


Annual Return

14 February 2012


Termination of appointment, secretary - Andrew Wood


Copies of documents filed at Companies House can be obtained from Companies House, Crown Way, Cardiff CF14 3UZ or through Companies House Direct at 



3.                  Documents published or sent to shareholders or filed with the UKLA National Storage Mechanism




31 August 2011

Interim Report for 6 months to 30 June 2011



Copies of all the above documents may be obtained from the Company Secretary at the Company's Registered Office:


This annual information update is filed pursuant to Prospectus Rule 5.2 made by the Financial Services Authority and not for any other purpose and by filing this annual information update neither the Company, nor any other person, takes any responsibility for, or makes any representation, express or implied, as to the accuracy or completeness of, the information contained or referred to below herein. The information referred to below is not necessarily up to date as at the date of this annual information update and the Company does not undertake any obligation to update any such information in the future. Furthermore, such information may have been prepared in accordance with the laws or regulations of a particular jurisdiction and may not comply with or meet the relevant standards of disclosure in any other jurisdiction. Neither this annual information update, nor the information referred to below constitutes, by virtue of this communication, an offer of any securities addressed to any person and should not be relied on by any person.




Oxford BioMedica plc

Medawar Centre

Robert Robinson Avenue

The Oxford Science Park




17 April 2012

This information is provided by RNS
The company news service from the London Stock Exchange